Latest

University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆ University of Galway to Lead New €64.5m Research Ireland Rinn Medical Devices Centre ◆ Chanelle Pharma Renews Historic Partnership with Galway Races Summer Festival 2026 ◆ The Distortion of Irish GDP: How 'Phantom Exports' Are Reshaping the Biopharma Landscape ◆ The Anatomy of a Biologics Warning Letter: Deconstructing Genzyme Waterford’s FDA Audit ◆ The Dublin-Backed Roll-Up Reshaping UK Pharma Packaging: Inside Woodberry's Double Acquisition ◆ The Pill That Promised a Revolution: Why Eli Lilly's Foundayo Is Launching Slower Than Wall Street Expected ◆ Speed Over Scrutiny? The High-Stakes Gamble Behind the NHS's New Fast-Track Drug Pilots ◆ A Global Milestone for Wellness: Chanelle McCoy Health Secures Historic Dual SFDA and European Novel Food Regulatory Approvals ◆

Markets · 15 min delay

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

ISEQ9,241.3▲ +0.62%

NBI4,187.6▲ +1.14%

PFE28.42▼ -0.38%

AZN74.18▲ +0.81%

NVO103.55▲ +2.07%

ROG261.40▼ -0.55%

ABBV174.92▲ +0.29%

EUR/USD1.0842▼ -0.12%

Harvoni

Ledipasvir/sofosbuvir

An oral once-daily single-tablet regimen used to treat chronic hepatitis C.

HCV NS5A and NS5B inhibitor

Generic name

Ledipasvir/sofosbuvir

Brand name

Harvoni

What Harvoni is used for

Ledipasvir/sofosbuvir (Harvoni) is an oral once-daily single-tablet regimen used to treat chronic hepatitis C. It belongs to the HCV NS5A and NS5B inhibitor class.

Explore more

Drug Shortages Tracker FDA Approvals US Clinical Trials Full drug directory

Sources: drug label, approval and manufacturer data from the U.S. FDA via the openFDA API; shortage status from the FDA Drug Shortage Database. This page is a plain-English summary for general information and is not medical advice. It is not exhaustive and may not reflect the latest label — always consult the official prescribing information and your clinician or pharmacist. Brand availability, indications and approvals differ between the US, EU/Ireland (EMA/HPRA) and other regions.